Advertisement

Cardiovascular considerations of pediatric ESRD

  • U. Querfeld

Abstract

Renal replacement therapy in the form of hemodialysis (HD), peritoneal dialysis (PD), and transplantation (TX) is now available for children of all ages and adolescents with end-stage renal disease (ESRD) in most countries of the western world. While these advances in therapy have been a blessing for many families, permitting survival of children affected by ESRD into adulthood, the long-term prognosis of young adult patients is guarded by the fact that mortality from cardiac disease (in the age group of 25-34 years) is excessively high, resembling the cardiac mortality of elderly patients (75 years and older) in the general population1. This chapter focuses on risk factors for this epidemic and their possible prevention in patients with ESRD, especially those treated with PD.

Keywords

Peritoneal Dialysis Coronary Artery Calcification Dialysis Patient Continuous Ambulatory Peritoneal Dialysis Peritoneal Dialysis Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Meyer KB, Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: report from the National Kidney Foundation Task Force on cardiovascular disease. J Am Soc Nephrol. 1998;9:S31–42.PubMedGoogle Scholar
  2. 2.
    Chavers BM, Li S, Collins AJ, Herzog CA. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int. 2002;62:648–53.PubMedCrossRefGoogle Scholar
  3. 3.
    US Renal Data System. USRDS 2000 Annual data report. Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; June 2000:2.Google Scholar
  4. 4.
    USRDS report. Excerpts from United States Renal Data System 1997 Annual Data Report. Am J Kidney Dis. 1997;30:S1–213.Google Scholar
  5. 5.
    Querfeld U. Is atherosclerosis accelerated in young patients with end-stage renal disease? The contribution of paediatric nephrology. Nephrol Dial Transplant. 2002;17:719–22.PubMedCrossRefGoogle Scholar
  6. 6.
    Luke RG. Chronic renal failure — a vasculopathic state. N Engl J Med. 1998;339:841–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Chavers B, Schnaper HW. Risk factors for cardiovascular disease in children on maintenance dialysis. Adv Ren Replace Ther. 2001;8:180–90.PubMedCrossRefGoogle Scholar
  8. 8.
    McGill HCJ, McMahan CA, Zieske AW et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vase Biol. 2000;20:1998–2004.CrossRefGoogle Scholar
  9. 9.
    Berenson GS, Srinivasan SR, Bao W, Newman WP3, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338:1650–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Parfrey PS. Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant. 2000;15(Suppl 5):58–68.PubMedCrossRefGoogle Scholar
  11. 11.
    Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Querfeld U. Undertreatment of cardiac risk factors in adolescents with renal failure. Perit Dial Int. 2001;21(Suppl 3):S285–9.PubMedGoogle Scholar
  13. 13.
    Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1995;6:177–83.PubMedGoogle Scholar
  14. 14.
    Collins AJ, Hao W, Xia H et al. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis. 1999;34:1065–74.PubMedCrossRefGoogle Scholar
  15. 15.
    Locatelli F, Marcelli D, Conte F et al. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol. 2001;12:2411–7.PubMedGoogle Scholar
  16. 16.
    Vonesh EF, Moran J. Mortality in end-stage renal disease: a reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1999;10:354–65.PubMedGoogle Scholar
  17. 17.
    Velasquez MT, Lew SQ, von Albertini B, Mishkin GJ, Bosch JP. Control of hypertension is better during hemodialysis than during continuous ambulatory peritoneal dialysis in ESRD patients. Clin Nephrol. 1997;48:341–5.PubMedGoogle Scholar
  18. 18.
    Shoda J, Nakamoto H, Okada H, Suzuki H. Impact of introduction of continuous ambulatory peritoneal dialysis on blood pressure: analysis of 24-hour ambulatory blood pressure. Adv Perit Dial. 2000;16:97–101.PubMedGoogle Scholar
  19. 19.
    Lingens N, Soergel M, Loirat C, Busch C, Lemmer B, Schärer K. Ambulatory blood pressure monitoring in paediatric patients treated by regular haemodialysis and peritoneal dialysis. Pediatr Nephrol. 1995;9:167–72.PubMedCrossRefGoogle Scholar
  20. 20.
    Koc M, Toprak A, Tezcan H, Bihorac A, Akoglu E, Ozener IC. Uncontrolled hypertension due to volume overload contributes to higher left ventricular mass index in CAPD patients. Nephrol Dial Transplant. 2002;17:1661–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Zucchelli P, Santoro A, Zuccala A. Genesis and control of hypertension in hemodialysis patients. Semin Nephrol. 1988;8:163–8.PubMedGoogle Scholar
  22. 22.
    Gunal AI, Duman S, Ozkahya M et al. Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis. 2001;37:588–93.PubMedCrossRefGoogle Scholar
  23. 23.
    Mitsnefes MM, Daniels SR, Schwartz SM, Khoury P, Strife CF. Changes in left ventricular mass in children and adolescents during chronic dialysis. Pediatr Nephrol. 2001;16:318–23.PubMedCrossRefGoogle Scholar
  24. 24.
    Holtta T, Happonen JM, Ronnholm K, Fyhrquist F, Holmberg C. Hypertension, cardiac state, and the role of volume overload during peritoneal dialysis. Pediatr Nephrol. 2001;16:324–31.PubMedCrossRefGoogle Scholar
  25. 25.
    Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol. 2000;14:898–902.PubMedCrossRefGoogle Scholar
  26. 26.
    Querfeld U. Disturbances of lipid metabolism in children with chronic renal failure. Pediatr Nephrol. 1993;7:749–57.PubMedCrossRefGoogle Scholar
  27. 27.
    Wanner C, Krane V. Uremia-specific alterations in lipid metabolism. Blood Purif. 2002;20:451–3.PubMedCrossRefGoogle Scholar
  28. 28.
    Ramos JM, Heaton A, McGurk JG, Ward MK, Kerr DN. Sequential changes in serum lipids and their subfractions in patients receiving continuous ambulatory peritoneal dialysis. Nephron. 1983;35:20–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Little J, Phillips L, Russell L, Griffiths A, Russell GI, Davies SJ. Longitudinal lipid profiles on CAPD: their relationship to weight gain, comorbidity, and dialysis factors. J Am Soc Nephrol. 1998;9:1931–9.PubMedGoogle Scholar
  30. 30.
    Querfeld U, Salusky IB, Nelson P, Foley J, Fine RN. Hyperlipidemia in pediatric patients undergoing peritoneal dialysis. Pediatr Nephrol. 1988;2:447–52.PubMedCrossRefGoogle Scholar
  31. 31.
    Querfeld U, LeBoeuf RC, Salusky IB, Nelson P, Laidlaw S, Fine RN. Lipoproteins in children treated with continuous peritoneal dialysis. Pediatr Res. 1991;29:155–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Saku K, Sasaki J, Naito S, Arakawa K. Lipoprotein and apolipoprotein losses during continuous ambulatory peritoneal dialysis. Nephron. 1989;51:220–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Drueke TB, Khoa TN, Massy ZA, Witko-Sarsat V, Lacour B, Descamps-Latscha B. Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int. 2001;78(Suppl):S114–9.CrossRefGoogle Scholar
  34. 34.
    Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int. 1994;46:869–76.PubMedCrossRefGoogle Scholar
  35. 35.
    Holvoet P, Donck J, Landeloos M et al. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost. 1996;76:663–9.PubMedGoogle Scholar
  36. 36.
    Miyazaki H, Matsuoka H, Itabe H et al. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation. 2000;101:1002–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Roob JM, Rabold T, Hayn M et al. Ex vivo low-density lipoprotein oxidizability and in vivo lipid peroxidation in patients on CAPD. Kidney Int. 2001;78(Suppl):S128–36.CrossRefGoogle Scholar
  38. 38.
    Serdyuk AP, Morton RE. Resistance of lipoproteins from continuous ambulatory peritoneal dialysis patients to in vitro oxidation. Metabolism. 1997;46:833–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Miyata T, Izuhara Y, Sakai H, Kurokawa K. Carbonyl stress: increased carbonyl modification of tissue and cellular proteins in uremia. Perit Dial Int. 1999;19(Suppl 2):S58–61.PubMedGoogle Scholar
  40. 40.
    Sakata N, Imanaga Y, Meng J et al. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis. 1998;141:61–75.PubMedCrossRefGoogle Scholar
  41. 41.
    Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med. 1996;28:419–26.PubMedCrossRefGoogle Scholar
  42. 42.
    Mykytyn K, Nishimura DY, Searby CC et al. Identification of the gene (BBS1) most commonly involved in Bardet-Biedl syndrome, a complex human obesity syndrome. Nat Genet. 2002;31:435–8.PubMedGoogle Scholar
  43. 43.
    Schaefer F, Klaus G, Mehls O. Peritoneal transport properties and dialysis dose affect growth and nutritional status in children on chronic peritoneal dialysis. Mid-European Pediatric Peritoneal Dialysis Study Group. J Am Soc Nephrol. 1999;10:1786–92.PubMedGoogle Scholar
  44. 44.
    Jager KJ, Merkus MP, Huisman RM et al. Nutritional status over time in hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 2001;12:1272–9.PubMedGoogle Scholar
  45. 45.
    Nordfors L, Heimburger O, Lonnqvist F et al. Fat tissue accumulation during peritoneal dialysis is associated with a polymorphism in uncoupling protein 2. Kidney Int. 2000;57:1713–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Davies SJ, Russell L, Bryan J, Phillips L, Russell GI. Impact of peritoneal absorption of glucose on appetite, protein catabolism and survival in CAPD patients. Clin Nephrol. 1996;45:194–8.PubMedGoogle Scholar
  47. 47.
    Kobayashi S, Maejima S, Ikeda T, Nagase M. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2000;15:65–70.PubMedCrossRefGoogle Scholar
  48. 48.
    Mak RH. Insulin resistance in uremia: effect of dialysis modality. Pediatr Res. 1996;40:304–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Wong TY, Chan JC, Szeto CC, Leung CB, Li PK. Clinical and biochemical characteristics of type 2 diabetic patients on continuous ambulatory peritoneal dialysis: relationships with insulin requirement. Am J Kidney Dis. 1999;34:514–20.PubMedCrossRefGoogle Scholar
  50. 50.
    Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524–38.PubMedCrossRefGoogle Scholar
  51. 51.
    Drueke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106:2212–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Block GA, TE, Levin NW, Port FK. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607–17.PubMedCrossRefGoogle Scholar
  53. 53.
    Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca X PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131–8.PubMedGoogle Scholar
  54. 54.
    Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1995;6:184–91.PubMedGoogle Scholar
  55. 55.
    Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int. 1990;38:931–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Eifinger F, Wahn F, Querfeld U et al. Coronary artery calcifications in children and young adults treated with renal replacement therapy. Nephrol Dial Transplant. 2000;15:1892–4.PubMedCrossRefGoogle Scholar
  57. 57.
    Oh J, Wunsch R, Turzer M et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation. 2002;106:100–5.PubMedCrossRefGoogle Scholar
  58. 58.
    Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Americk A, Greaser L, Elashoff RM, Salusky IB. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Eng J Med. 2000;342:1478–83.CrossRefGoogle Scholar
  59. 59.
    Querfeld U, Lang M, Friedrich JB, Kohl B, Fiehn W, Schärer K. Lipoprotein(a) serum levels and apolipoprotein(a) phenotypes in children with chronic renal disease. Pediatr Res. 1993;34:772–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Nowak-Göttl U, Debus O, Findeisen M et al. Lipoprotein(a): its role in childhood thromboembolism. Pediatrics. 1997;99:E11.PubMedCrossRefGoogle Scholar
  61. 61.
    Kronenberg F, Konig P, Neyer U et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6:110–20.PubMedGoogle Scholar
  62. 62.
    Wanner C, Bartens W, Walz G, Nauck M, Schollmeyer P. Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients. Nephrol Dial Transplant. 1995;10:75–81.PubMedGoogle Scholar
  63. 63.
    Podrez EA, O’Neil J, Salomon RG, Schreiber M J, Hoff HF. Measurement of oxidation in plasma Lp(a) in CAPD patients using a novel ELISA. Kidney Int. 1998;54:637–45.PubMedCrossRefGoogle Scholar
  64. 64.
    Querfeld U, Haffner D, Wuhl E et al. Treatment with growth hormone increases lipoprotein(a) serum levels in children with chronic renal insufficiency. Eur J Pediatr. 1996;155:913.PubMedCrossRefGoogle Scholar
  65. 65.
    Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest. 2001;120:1883–17.PubMedCrossRefGoogle Scholar
  66. 66.
    Hulse M, Johnson S, Ferrieri P. Agrobacterium infections in humans: experience at one hospital and review. Clin Infect Dis. 1993;16:112–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Tokars JI, Miller ER, Stein G. New national surveillance system for hemodialysis-associated infections: initial results. Am J Infect Control. 2002;30:288–95.PubMedCrossRefGoogle Scholar
  68. 68.
    Furth SL, Donaldson LA, Sullivan EK, Watkins SL. Peritoneal dialysis catheter infections and peritonitis in children: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol. 2000;15:179–82.PubMedCrossRefGoogle Scholar
  69. 69.
    Fried LF, Bernardini J, Johnston JR, Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol. 1996;7:2176–82.PubMedGoogle Scholar
  70. 70.
    Carracedo J, Ramirez R, Madueno JA et al. Cell apoptosis and hemodialysis-induced inflammation. Kidney Int. 2002;61(Suppl 80):89–93.CrossRefGoogle Scholar
  71. 71.
    Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin JM. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int. 2002;62:1417–22.PubMedCrossRefGoogle Scholar
  72. 72.
    Stenvinkel P, Heimburger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis. 2002;39:274–82.PubMedCrossRefGoogle Scholar
  73. 73.
    Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int. 2002;61(Suppl 80):99–102.CrossRefGoogle Scholar
  74. 74.
    Herzig KA, Purdie DM, Chang W et al. Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J Am Soc Nephrol. 2001;12:814–21.PubMedGoogle Scholar
  75. 75.
    Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol. 1995;5:2024–31.PubMedGoogle Scholar
  76. 76.
    Tornig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol. 1996;7:667–75.PubMedGoogle Scholar
  77. 77.
    Nayir A, Bilge I, Kilicaslan I, Ander H, Emre S, Sirin A. Arterial changes in paediatric haemodialysis patients undergoing renal transplantation. Nephrol Dial Transplant. 2001;16:2041–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM. Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vase Biol. 1998;18:535–41.CrossRefGoogle Scholar
  79. 79.
    Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996;27:394–401.PubMedCrossRefGoogle Scholar
  80. 80.
    Simons PC, Algra A, Bots ML, Grobbee DE, van der GY. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease). Circulation. 1999;100:951–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Pannier B, Guerin AP, Marchais S J, Metivier F, Safar ME, London GM. Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease. Kidney Int. 2000;57:1091–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Peppa-Patrikiou M, Scordili M, Antoniou A, Giannaki M, Dracopoulou M, Dacou-Voutetakis C. Carotid atherosclerosis in adolescents and young adults with IDDM. Relation to urinary endothelin, albumin, free Cortisol, and other factors. Diabetes Care. 1998;21:1004–7.PubMedCrossRefGoogle Scholar
  83. 83.
    Lavrencic A, Kosmina B, Keber I, Videcnik V, Keber D. Carotid intima-media thickness in young patients with familial hypercholesterolaemia. Heart. 1996;76:321–5.PubMedCrossRefGoogle Scholar
  84. 84.
    Groothoff JW, Gruppen MP, de Groot E et al. Increased arterial stiffness in young adults with end-stage renal disease since childhood. Pediatr Nephrol. 2002;17:C125(abstract).Google Scholar
  85. 85.
    Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24:1468–74.PubMedCrossRefGoogle Scholar
  86. 86.
    Kari JA, Donald AE, Vallance DT et al. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int. 1997;52:468–72.PubMedCrossRefGoogle Scholar
  87. 87.
    Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Abnormalities of endothelial function in patients with predialysis renal failure. Heart. 2000;83:205–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014–21.PubMedCrossRefGoogle Scholar
  89. 89.
    Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999;99:2434–9.PubMedCrossRefGoogle Scholar
  90. 90.
    Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103:987–92.PubMedCrossRefGoogle Scholar
  91. 91.
    Wühl E, Fusch C, Schärer K, Mehls O, Schaefer F. Assessment of total body water in paediatric patients on dialysis. Nephrol Dial Transplant. 1996;11:75–80.PubMedCrossRefGoogle Scholar
  92. 92.
    Gong WK, Foong PP, Ramirez S, Murugasu B, Yap HK. Can dialysis adequacy be achieved by tailoring the dialysis prescription in an Asian pediatric population on nightly intermittent peritoneal dialysis? Adv Perit Dial. 1999;15:291–6.PubMedGoogle Scholar
  93. 93.
    de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995;25:1056–62.PubMedCrossRefGoogle Scholar
  94. 94.
    Islam KN, O’Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis. 2000;150:217–24.PubMedCrossRefGoogle Scholar
  95. 95.
    Sunder-Plassmann G, Fodinger M, Buchmayer H et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol. 2000;11:1106–16.PubMedGoogle Scholar
  96. 96.
    Baraldi E, Montini G, Zanconato S, Zacchello G, Zacchello F. Exercise tolerance after anaemia correction with recombinant human erythropoietin in end-stage renal disease. Pediatr Nephrol. 1990;4:623–6.PubMedCrossRefGoogle Scholar
  97. 97.
    Bostrom K. Insights into the mechanism of vascular calcification. Am J Cardiol. 2001;88:20E–22E.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2004

Authors and Affiliations

  • U. Querfeld

There are no affiliations available

Personalised recommendations